OLAPARIB VERSUS BEVACIZUMAB IN PLATINUM-RESISTANT OR RECCURENT OVARIAN/FALLOPIAN TUBE/PERITONEAL CANCER.CLINICAL BENEFITS AND RISK (META-ANALYSIS)

Dr. Ntumba Kabasele Clemence, *Wang Xue Feng, Mark Momoh Koroma, Samson Kaphera

ABSTRACT

Objective: This paper which aimed at comparing clinical outcomes of Olaparib and Bev in women who developed ovarian carcinoma. These trials outcomes included, first Overall Survival second Progression free Survival then the third is development of Adverse Events. Methods: Search strategies: randomized trial AND (Olaparib OR bevacizumab) AND (peritoneal cancer OR tubal cancer OR ovarian cancer) all advanced search. There after, data were extracted data from selected studies. Data extracted was entered on Excel and thereafter exported to SPSS and R for analysis. We used three random models for three outcomes separately as stated in the objective section. Statistical fit tests were performed and analyzed. Results: BEV exhibited longer PFS than OLA although the statistic difference was not significant was not statistically (es, 4.360 ([95% CI] -1.335 - 10.055), p>.05 in Bev; 0.149 (95% CI -2.234 to 2.531) p>.05 in Ola). On the other hand, Ola significantly reduced OS as compared with Bev (es, -0.775 (95% CI -1.115 to 5.716) p<.001 in Ola and 1.199 ([95% CI ]-1.638 to 4.036) p>.05 in Bev.). Bev resulted into lower AEs than Ola although the modification was not significant according to statistics performed (es, 0.491 ([95% CI] -3.156 to 4.137), p>.05) in Ola and -0.035 (95% CI -4.880 to 4.809), p>.05). Limitations: Our study used data that were reported in other studies. This is because meta-analyses have secondary reliability because they depend on the level of accuracy and truthfulness of previous studies. Moreover, the study did not account for confounding variables including BRCA mutation; a fact that has the potential to reduce the strength of evidence. Conclusions: The study shows that Olaparib might be statistically effective at the same level of therapeutic approach with Bevacizumab with PFS and OS. Adverse events risk in Olaparib and bevacizumab are almost similar in cases with resistance to platinum, recurrent cancer, fallopian tube or peritoneal cancer.

Keywords: Ovarian cancer, Tubal cancer, Bevacizumab, Peritoneal cancer, Olaparib and randomized clinical trial.